Ovarian Cancer Trials
Select Clinical Trial
Protocol Number: Aravive AVB500-OC-004/GOG 3059
Protocol Title: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer.
Eligibility: Women 18 years of age or older with confirmed recurrent, platinum-resistant, high-grade serious ovarian, fallopian tube, or peritoneal cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________